|
KMID : 1037520170330030089
|
|
Vascular Specialist International
2017 Volume.33 No. 3 p.89 ~ p.92
|
|
|
Cilostazol for Secondary Prevention of Stroke: Should the Guidelines Perhaps Be Extended?
|
|
Galyfos George
Sianou Argyri
|
|
|
Abstract
|
|
|
|
Cilostazol belongs to the new generation antiplatelet agents that have been introduced and studied regarding a potential role in cardiovascular disease prevention or treatment. Although data on peripheral artery disease are sufficient, and the drug has been recommended as first line treatment for intermittent claudication, it has not been approved nor recommended as far as cerebrovascular events are concerned. However, a great volume of randomized as well as pooled data has been published during the last years. Therefore, this review aims to describe the basic mechanisms of cilostazol’s action as well as to present all recent clinical data in order to conclude on whether official guidelines should be extended.
|
|
|
KEYWORD
|
|
|
Stroke, Secondary prevention, Guideline
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|